|
|
Research in Pharmaceutical Sciences، جلد ۱۸، شماره ۱، صفحات ۸۹-۹۹
|
|
|
| عنوان فارسی |
|
|
| چکیده فارسی مقاله |
|
|
| کلیدواژه‌های فارسی مقاله |
|
|
| عنوان انگلیسی |
A double-blind randomized clinical trial of Dracocephalum kotschyi Boiss. in the patients with diarrhea-predominant irritable bowel syndrome |
|
| چکیده انگلیسی مقاله |
Background and purpose : Irritable bowel syndrome (IBS) is a disease that shows its impacts on many populations worldwide. It is known as a functional disorder of the gastrointestinal tract followed by diarrhea and fecal inconsistency. Due to the lack of treatment in the allopathic medicine system for IBS, people in the western world use different herbs as alternative medicine. In the present study, we evaluated the dried extract of Dracocephalum kotschyi against IBS. Experimental approach : In a randomized, double-blinded, placebo-controlled clinical trial, 76 diarrhea-predominant IBS patients were randomly assigned to two equal groups: the control group (given the placebo capsule containing 250 mg of dibasic calcium phosphate) and the treatment groups (given the capsule containing 75 mg of the dry extract of D. kotschyi and 175 mg of dibasic calcium phosphate as filler). The study was conducted based on Rome III criteria. We studied symptoms included in Rome III criteria and divided the study into the duration of drug administration and four weeks after drug administration. These groups were compared with those of the control group. Findings/Results : Significant improvements were found in the quality of life, temperament, and IBS symptoms throughout the treatment duration. Quality of life, temperature, and IBS symptoms were slightly decreased in the treatment group 4 weeks after stopping the treatment. While concluding the study, we found D. kotschyi effective against IBS. Conclusion and implications : Whole extract of D. kotschyi modulated symptoms of IBS patients and improved their quality of life. |
|
| کلیدواژه‌های انگلیسی مقاله |
Diarrhea,Dracocephalum kotschyi,Irritable bowel syndrome,Persian medicine,Randomized controlled trial,ROME criteria. |
|
| نویسندگان مقاله |
| Parisa Heydari
Isfahan Pharmaceutical Sciences Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, I.R. Iran.
| Mustafa Ghanadian
Department of Pharmacognosy, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, I.R. Iran.
| Gholamreza Asghari
Gastroenterology and Hepatology Research Center, Kerman University of Medical Sciences, Kerman, I.R. Iran.
| Maryam Azimi
Department of Persian Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, I.R. Iran.
| Mahmoud Babaeian
Isfahan Gastroenterology and Hepatology Research Center, Isfahan University of Medical Sciences, Isfahan, I.R. Iran.
| Peyman Adibi
|
|
| نشانی اینترنتی |
http://rps.mui.ac.ir/index.php/jrps/article/view/2172 |
| فایل مقاله |
فایلی برای مقاله ذخیره نشده است |
| کد مقاله (doi) |
|
| زبان مقاله منتشر شده |
en |
| موضوعات مقاله منتشر شده |
|
| نوع مقاله منتشر شده |
Original Article |
|
|
|
برگشت به:
صفحه اول پایگاه |
نسخه مرتبط |
نشریه مرتبط |
فهرست نشریات
|